Reports
Sale
Global Adult Malignant Glioma Therapeutics Market Share, Size, Forecast: By Diseases Type: Glioblastoma Multiforme (GBM), Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Others; By Therapy Type; By Drug Class; By Route of Administration; By Treatment Centers; By Treatment Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Adult Malignant Glioma Therapeutics Market Outlook
The global adult malignant glioma therapeutics market size attained a value of USD 2.01 billion in 2023 driven by rising prevalence of cancer disorders. The market is anticipated to grow at a CAGR of 9.2% during the forecast period of 2024-2032 to attain a value of USD 4.45 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America and Asia Pacific to be the Significant Regional Markets for Adult Malignant Glioma Therapeutics
North America is anticipated to dominate the global market due to the presence of major product manufacturers, high research and development (R&D), growing healthcare expenditure, and trained personnel. Technological innovation is a major market driver in North America. According to the National Library of Medicine, approximately 17,000 new high-grade gliomas (HGG) cases are diagnosed in the United States each year. Primary malignant brain tumours account for approximately 3% of all cancer deaths, the majority (around 80%) of which are HGG . The rise in the incidence of the disease, a strong economy, high diagnosis rate owing to the awareness about healthcare among the population are the other major factors driving the adult malignant glioma therapeutics market.
Due to an increase in government awareness programmes and the number of generic drugs, Asia Pacific is estimated to account for the largest market share for adult malignant glioma therapeutics in the forecast period. The market's growth, however, is likely to be determined by the combined prospects in technology and opportunity in developing Asian countries such as China, Japan, India, and South Korea. The relatively large patient population requiring affordable care and improvements in health care infrastructure in rapidly developing countries that aid in the early detection of malignant gliomas are likely to drive the adult malignant glioma therapeutics market.
Market Segmentations
Malignant brain tumours have a profound effect on both those who receive and those who deliver the diagnosis. Malignant gliomas, the most prevalent subtype of primary brain tumours, are aggressive, highly invasive, and neurologically damaging tumours that are among the most fatal human diseases.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The different therapies provided by the market are:
- Radiotherapy
- Chemotherapy
- Targeted therapy
- Others
Based on disease, the market is divided into:
- Anaplastic Astrocytoma
- Glioblastoma Multiforme
- Anaplastic Oligodendroglioma
- Others
The end-uses of the market are:
- Speciality Clinics
- Hospitals
- Cancer and Radiation Therapy Centres
- Others
The regional markets for adult malignant glioma therapeutics can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Prevalence of Cancer Related Disorders Propelling the Market Growth
The rising prevalence of cancer-related disorders worldwide and growing cases of brain tumours are the major factors driving the adult malignant glioma therapeutics market. The adoption of an unhealthy lifestyle, genetic modification/alteration, increased age, excessive exposure to radiation and family history with brain cancer are also propelling the market growth. Further, increased advancements in cancer treatment, a fast-expanding pipeline of innovative novel medications, and increased government support to accelerate the process of orphan drug approval are expected to bolster the market growth during the projection period. However, high treatment costs, loss of market exclusivity, post-patent expiration, and price reductions in branded drugs owing to competition from generic brands may impede the market growth.
Technological advancements in diagnosing glioma and analysing its progression through various imaging modalities are accelerating the market growth. For example, researchers have developed a new imaging technique that may help eliminate the malignant tumour from the human body. This imaging method may help surgeons locate the tumour with ease. The method also involves using an infra-red (IR) camera and an imaging reagent tozuleristide (BLZ-100). The agent contains a synthetic version of an amino acid compound found in scorpion venom. The primary goal of this procedure was to distinguish between healthy and tumour tissue. This aids in the retention of healthy tissue following surgery, increasing the overall efficiency of the procedure . Such discoveries are likely to favour the growth of the global adult malignant glioma therapeutics market in the coming years.
Key Players in the Global Market for Adult Malignant Glioma Therapeutics
The report gives a detailed analysis of the following key players in the global adult malignant glioma therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Arbor Pharmaceuticals, LLC
- AbbVie Inc.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diseases Type |
|
| Breakup by Therapy Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Treatment Centers |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Adult Malignant Glioma Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Adult Malignant Glioma Epidemiology Analysis
5.1 Overview (2016-2031)
5.2 North America Adult Malignant Glioma Epidemiology (2016-2031)
5.3 Europe Adult Malignant Glioma Epidemiology (2016-2031)
5.4 Asia-Pacific Adult Malignant Glioma Epidemiology (2016-2031)
5.5 Latin America Adult Malignant Glioma Epidemiology (2016-2031)
5.6 Middle East & Africa Adult Malignant Glioma Epidemiology (2016-2031)
6 Global Adult Malignant Glioma Therapeutics Market Overview
6.1 Global Adult Malignant Glioma Therapeutics Market Historical Value (2017-2023)
6.2 Global Adult Malignant Glioma Therapeutics Market Forecast Value (2024-2032)
7 Global Adult Malignant Glioma Therapeutics Market Landscape
7.1 Global Adult Malignant Glioma Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Adult Malignant Glioma Therapeutics: Product Landscape
7.2.1 Analysis by Diseases Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by Treatment Channel
7.2.5 Analysis by End User
8 Adult Malignant Glioma Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Adult Malignant Glioma Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Adult Malignant Glioma Therapeutics Market Segmentation
11.1 Global Adult Malignant Glioma Therapeutics Market by Diseases Type
11.1.1 Market Overview
11.1.2 Glioblastoma Multiforme (GBM)
11.1.3 Anaplastic Astrocytoma
11.1.4 Anaplastic Oligodendroglioma
11.1.5 Anaplastic Oligoastrocytoma
11.1.6 Others
11.2 Global Adult Malignant Glioma Therapeutics Market by Therapy Type
11.2.1 Market Overview
11.2.2 Surgery
11.2.3 Radiation Therapy
11.2.4 Chemotherapy
11.2.5 Targeted Therapy
11.2.6 Immunotherapy
11.2.7 Tumor treating fields (TTF) Therapy
11.2.8 Combination Therapy
11.2.9 Others
11.3 Global Adult Malignant Glioma Therapeutics Market by Drug Class
11.3.1 Market Overview
11.3.2 Alkylating Agents
11.3.3 Tyrosine Kinase Inhibitors
11.3.4 Checkpoint Inhibitors
11.3.5 Angiogenesis Inhibitors
11.3.6 Other
11.4 Global Adult Malignant Glioma Therapeutics Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parentals
11.4.4 Others
11.5 Global Adult Malignant Glioma Therapeutics Market by Treatment Centers
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Ambulatory Surgical Centres
11.5.5 Cancer Research Institutes
11.5.6 Others
11.6 Global Adult Malignant Glioma Therapeutics Market by Treatment Channel
11.6.1 Market Overview
11.6.2 Public
11.6.3 Private
11.7 Global Adult Malignant Glioma Therapeutics Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Adult Malignant Glioma Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Adult Malignant Glioma Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Adult Malignant Glioma Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Adult Malignant Glioma Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Adult Malignant Glioma Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Mylan N.V.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Teva Pharmaceutical Industries Ltd.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Sanofi
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Pfizer Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 GlaxoSmithKline plc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Novartis AG
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Bayer AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Merck & Co., Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Allergan
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 AstraZeneca
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Johnson & Johnson Private Limited
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Abbott
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Bausch Health Companies Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Sun Pharmaceutical Industries Ltd.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Aurobindo Pharma
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Lupin
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Amneal Pharmaceuticals LLC.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Genetech Inc.
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Emcure
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
24 Adult Malignant Glioma Therapeutics Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2023, the global market for adult malignant glioma therapeutics reached a value of USD 2.01 billion.
The market is anticipated to grow at a CAGR of 9.2% during the forecast period of 2024-2032 to reach a value of USD 4.45 million by 2032.
The major drivers of the market include the growing cases of brain tumours, adoption of an unhealthy lifestyle, excessive exposure to radiation, family history with brain cancer, fast-expanding pipeline of innovative novel medications, increased government support, and technological advancements.
The rising prevalence of cancer-related disorders and increased advancements in cancer treatment are the key industry trends propelling the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different therapies provided by the market are radiotherapy, chemotherapy, and targeted therapy, among others.
Based on disease, the market is divided into anaplastic astrocytoma, glioblastoma multiforme, and anaplastic oligodendroglioma, among others.
The end-uses of the market are speciality clinics, hospitals, and cancer and radiation therapy centres, among others.
The major players in the industry are Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, LLC, and AbbVie Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER